Chronic kidney disease and cardiovascular therapeutics: Time to close the evidence gaps

Journal of the American College of Cardiology

Volumn 58, Issue 11, 2011, Pages 1162-1164

  Chang, Tara I ^a   Chertow, Glenn M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

beta adrenergic antagonists; cardiovascular disease; chronic kidney disease; heart failure; meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PLACEBO; RAMIPRIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

EID: 80052372787     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.06.010     Document Type: Editorial

References (26)

1. National Kidney Foundation Part 4 Definition and classification of stages of chronic kidney disease Am J Kidney Dis 39 Suppl 1 2002 S46 S75
2. N. Abutaleb Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components Nephrol Dial Transplant 22 2007 2728 2729 (Pubitemid 47365548)
3. G.M. Kirsztajn, J.H.R. Suassuna, and M.G. Bastos Dividing stage 3 of chronic kidney disease (CKD): 3a and 3b Kidney Int 76 2009 462 463
4. National Kidney Foundation KDOQI Guidelines KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease [guidelines online] http://www.kidney.org/professionals/KDOQI/guidelines-bp/ index.htm 2002 Accessed May 25, 2010
5. J.T. Heywood, G.C. Fonarow, M.R. Costanzo ADHERE Scientific Advisory Committee and Investigators High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database J Card Fail 13 2007 422 430 (Pubitemid 47179911)
6. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
7. C.S. Fox, P. Muntner, and A.Y. Chen Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and nonST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry Circulation 121 2010 357 365
8. M.G. Shlipak, P.A. Heidenreich, H. Noguchi, G.M. Chertow, W.S. Browner, and M.B. McClellan Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients Ann Intern Med 137 2002 555 562
9. E.M. Gibney, A.W. Casebeer, and L.M. Schooley Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study Kidney Int 68 2005 826 832 (Pubitemid 43323140)
10. S.G. Coca, H.M. Krumholz, A.X. Garg, and C.R. Parikh Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease JAMA 296 2006 1377 1384 (Pubitemid 44427424)
11. S.V. Badve, M.A. Roberts, and C.M. Hawley Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis J Am Coll Cardiol 58 2011 1152 1161
12. K. Norris, J. Bourgoigne, J. Gassman AASK Study Group Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial Am J Kidney Dis 48 2006 739 751 (Pubitemid 44740048)
13. F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, and P.W. Armstrong Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
14. U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2010 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
15. G. Cice, A. Di Benedetto, and S. D'Isa Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial J Am Coll Cardiol 56 2010 1701 1708
16. F. Zannad, M. Kessler, and P. Lehert Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 2006 1318 1324 (Pubitemid 44435184)
17. B.C. Fellström, A.G. Jardine, R.E. Schmieder AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
18. C. Wanner, V. Krane, W. Marz German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
19. W.C. Winkelmayer, R. Levin, and S. Setoguchi Associations of kidney function with cardiovascular medication use after myocardial infarction Clin J Am Soc Nephrol 3 2008 1415 1422
20. W.C. Winkelmayer, D.M. Charytan, M.A. Brookhart, R. Levin, D.H. Solomon, and J. Avorn Kidney function and use of recommended medications after myocardial infarction in elderly patients Clin J Am Soc Nephrol 1 2006 796 801
21. T.I. Chang, M. Desai, D.H. Solomon, and W.C. Winkelmayer Kidney function and long-term medication adherence after myocardial infarction in the elderly Clin J Am Soc Nephrol 6 2011 864 869
22. K.C. Abbott, E.M. Bohen, and C.M. Yuan Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system Am J Kidney Dis 47 2006 593 603
23. A.S. Desai, K. Swedberg, J.J. McMurray CHARM Program Investigators Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program J Am Coll Cardiol 50 2007 1959 1966 (Pubitemid 350046342)
24. I.S. Anand, K. Bishu, T.S. Rector, A. Ishani, M.A. Kuskowski, and J.N. Cohn Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure Circulation 120 2009 1577 1584
25. C. Baigent, M.J. Landray, C. Reith SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
26. U.S. Department of Health and Human Services NIH Launches Multicenter Clinical Trial to Test Blood Pressure Strategy [online press release] http://www.nih.gov/news/health/oct2009/nhlbi-29.htm Accessed May 20, 2010